Exosomes-coated bcl-2 siRNA inhibits the growth of digestive system tumors both in vitro and in vivo

Tao, Hongyu; Xu, Huanli; Zuo, Ling; Liu, Cong; Qiao, Gan; Guo, Mingyue; Zheng, Lanhong; Leitgeb, Maja; Lin, Xiukun

doi:10.1016/j.ijbiomac.2020.06.052

Cited by 46 publications

(24 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They demonstrated that milk-derived exosomes could deliver siRNA to lung cancer cells. Furthermore, Hong et al verified that milk-derived exosomes carrying Bcl-2-siRNA could efficiently penetrate the cell membrane and suppress the invasion and migration of pancreatic cancer cells by downregulating matrix metalloproteinases 2 (MMP2), MMP9, vimentin, and N-cadherin ( Tao et al, 2020 ). However, further evidence is needed to support the anti-cancer effects of milk-derived exosomes carrying siRNA in vivo .…”

Section: Characteristics and Function Of Exosomesmentioning

confidence: 99%

Exosomes as Drug Carriers in Anti-Cancer Therapy

Chen

Wang

Zhu

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Over the years, there has been a high demand for developing new safe and effective drug carriers for cancer therapy. Emerging studies have indicated that exosomes can serve as potent therapeutic carriers since they offer low immunogenicity, high stability, innate and acquired targetability, and the stimulation of anti-cancer immune responses. Yet, the development of exosome-based drug delivery systems remains challenging due to their heterogeneity, low yield, and limited drug loading efficiency. Herein, we summarized the current application of exosomes derived from different cells as drug carriers in anti-cancer therapy in vitro and in vivo. We also discussed the challenges and prospects of exosome-based drug delivery systems in cancer therapy.

show abstract

Section: Characteristics and Function Of Exosomesmentioning

confidence: 99%

Exosomes as Drug Carriers in Anti-Cancer Therapy

Chen

Wang

Zhu

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Engineered exosomes could carry oncogenic KRASG12D siRNA or shRNA into human pancreatic orthotopic tumors that suppress KrasG12D expression, inhibit advanced metastatic disease, and increase overall survival (Kamerkar et al, 2017;Mendt et al, 2018;Rakhit et al, 2019). Exosomes isolated from human embryonic kidney 293 cells (HEK293) and mesenchymal stem cells that transport PLK-1 siRNA to bladder cancer cells in vitro and those isolated from bovine milk that deliver bcl-2 siRNA to human pancreatic cancer Panc28 and human colorectal cancer HCT-116 cells result in selective gene silencing, both of which have been reported (Greco et al, 2016;Tao et al, 2020). Targeting peptide tLyp-1--modified exosomes by tLyp-1-lamp2b plasmids-loading SOX2 siRNA isolated from HEK293 cells have been proved to have high transfection efficiency into lung cancer and cancer stem cells which were able to knockdown the target gene SOX2 of cancer cells and reduce the stemness of cancer stem cells (Bai et al, 2020).…”

Section: Curmentioning

confidence: 99%

A Review on Drug Delivery System for Tumor Therapy

et al. 2021

View full text Add to dashboard Cite

In recent years, with the development of nanomaterials, the research of drug delivery systems has become a new field of cancer therapy. Compared with conventional antitumor drugs, drug delivery systems such as drug nanoparticles (NPs) are expected to have more advantages in antineoplastic effects, including easy preparation, high efficiency, low toxicity, especially active tumor-targeting ability. Drug delivery systems are usually composed of delivery carriers, antitumor drugs, and even target molecules. At present, there are few comprehensive reports on a summary of drug delivery systems applied for tumor therapy. This review introduces the preparation, characteristics, and applications of several common delivery carriers and expounds the antitumor mechanism of different antitumor drugs in delivery carriers in detail which provides a more theoretical basis for clinical application of personalized cancer nanomedicine in the future.

show abstract

“…It is well known that exosomes have the innate ability to cross biological barriers; thus, engineered exosomes could efficiently facilitate cellular uptake of miRNAs and significantly reduce cancer proliferation (80). Professor Lin has proved that milk-derived exosomes can transport across the gastrointestinal barrier (99), and small interfering RAN (bcl-2 siRNA) encapsulated by milk-derived exosomes can effectively pass through cell membranes and inhibit the growth of cancer cells (84). Additionally, a study demonstrated…”

Section: Application In Crossing Biological Barriersmentioning

confidence: 99%

Exosomes as Smart Nanoplatforms for Diagnosis and Therapy of Cancer

et al. 2021

View full text Add to dashboard Cite

Exosomes are composed of a lipid bilayer membrane, containing proteins, nucleic acids, DNA, RNA, etc., derived from donor cells. They have a size range of approximately 30-150 nm. The intrinsic characteristics of exosomes, including efficient cellular uptake, low immunogenicity, low toxicity, intrinsic ability to traverse biological barriers, and inherent targeting ability, facilitate their application to the drug delivery system. Here, we review the generation, uptake, separation, and purification methods of exosomes, focusing on their application as carriers in tumor diagnosis and treatment, especially in brain tumors, as well as the patent applications of exosomes in recent years.

show abstract

Exosomes-coated bcl-2 siRNA inhibits the growth of digestive system tumors both in vitro and in vivo

Cited by 46 publications

References 38 publications

Exosomes as Drug Carriers in Anti-Cancer Therapy

Exosomes as Drug Carriers in Anti-Cancer Therapy

A Review on Drug Delivery System for Tumor Therapy

Exosomes as Smart Nanoplatforms for Diagnosis and Therapy of Cancer

Contact Info

Product

Resources

About